Skip to main content
All lobbying clients

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)

Lobbying client · District of Columbia · filed 2025 to 2026

Represents pharmaceutical research and biotechnology companies

$3,330,000 Reported spend
35 Filings counted
7 Outside firms hired
8 Bills named

Spend is reported income plus in-house expenses across 35 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 7 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

 Who filed for this client 7

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 8
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    11 filings
  • S. 832
    EPIC Act of 2025
    9 filings
  • H.R. 2214
    DRUG Act
    7 filings
  • H.R. 1
    One Big Beautiful Bill Act
    5 filings
  • H.R. 4317
    PBM Reform Act of 2025
    2 filings
  • H.R. 7391
    Community Health Center Drug Pricing Protection Act
    2 filings
  • S. 3345
    PBM Price Transparency and Accountability Act
    2 filings
  • H.R. 7148
    Consolidated Appropriations Act, 2026
    1 filing
 Reported by year 2 years
  • 2026 $1,450,000 13 filings
  • 2025 $1,880,000 22 filings
 Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 4
  • SENATE 22
  • HOUSE OF REPRESENTATIVES 21
  • Health & Human Services, Dept of (HHS) 14
  • Food & Drug Administration (FDA) 7
 Recent filings 36 total
Q3 report
CAPITOL COUNSEL LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
ARNOLD & PORTER KAYE SCHOLER LLP
3rd Quarter 2026 (July 1 - Sep 30) · $290,000 income · posted Oct 16, 2026
View →
Q3 report
DESIMONE CONSULTING, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 13, 2026
View →
Q3 report
ADVANCED POLICY CONSULTING, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $40,000 income · posted Oct 13, 2026
View →
Q2 report
CAPITOL COUNSEL LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 19, 2026
View →
Q2 report
ADVANCED POLICY CONSULTING, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $40,000 income · posted Jul 17, 2026
View →
Q2 report
ARNOLD & PORTER KAYE SCHOLER LLP
2nd Quarter 2026 (Apr 1 - June 30) · $380,000 income · posted Jul 17, 2026
View →
Q2 report
DESIMONE CONSULTING, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $30,000 income · posted Jul 14, 2026
View →
Q1 report
CAPITOL COUNSEL LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
ARNOLD & PORTER KAYE SCHOLER LLP
1st Quarter 2026 (Jan 1 - Mar 31) · $420,000 income · posted Apr 20, 2026
View →
Q1 terminationNo activity
TIBER CREEK HEALTH STRATEGIES, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026
View →
Q1 report
DESIMONE CONSULTING, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 14, 2026
View →
Q1 report
ADVANCED POLICY CONSULTING, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Apr 14, 2026
View →
Q4 report
CAPITOL COUNSEL LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $40,000 income · posted Jan 20, 2026
View →
Q4 reportNo activity
TIBER CREEK HEALTH STRATEGIES, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · $50,000 income · posted Jan 20, 2026
View →
Q4 report
ADVANCED POLICY CONSULTING, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $40,000 income · posted Jan 17, 2026
View →
Q4 report
DESIMONE CONSULTING, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $40,000 income · posted Jan 17, 2026
View →
Q4 report
ARNOLD & PORTER KAYE SCHOLER LLP
4th Quarter 2025 (Oct 1 - Dec 31) · $240,000 income · posted Jan 16, 2026
View →
Q3 reportNo activity
TIBER CREEK HEALTH STRATEGIES, INC.
3rd Quarter 2025 (July 1 - Sep 30) · $50,000 income · posted Oct 19, 2025
View →
Q3 report
CAPITOL COUNSEL LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2025
View →

Showing the 20 most recent of 36 filings. Search the explorer for "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem